Introduction {#Sec1}
============

Smoking tobacco is the number one cause of preventable death in the United States, with 480,000 individuals dying each year from cigarette use and second-hand smoke exposure^[@CR1]^. Nicotine, the main reinforcer in tobacco, is a primary reinforcer that has been shown to support self-administration, increase and sensitize locomotor activity, and drive drug-seeking behavior^[@CR2],[@CR3]^. Additionally, nicotine enhances the reinforcing effects and incentive motivation of stimuli that accompany tobacco use^[@CR4]^.

Nicotinic acetylcholine receptors (nAChR) are necessary for both the primary reinforcing and reinforcement enhancing effects of nicotine. Activation of nAChRs in the nucleus accumbens or in the VTA can directly increase dopamine release in the striatum^[@CR5],[@CR6]^ and systemic nAChR antagonism decreases nicotine self-administration^[@CR7]--[@CR9]^. In addition, NAc nAChRs modulate dopamine release in a frequency dependent manner^[@CR10]^. Dopamine neurons switch between tonic (\~4--5 Hz) and phasic (2--5 spikes at 20--100 Hz) patterns of firing during the presentation of reinforcers or reward-related cues^[@CR11]--[@CR13]^. Nicotine is thought to enhance the contrast between baseline firing and reward-related firing by decreasing dopamine release to tonic firing rates while increasing dopamine release to phasic firing patterns in the NAc^[@CR14]^. This is hypothesized to enhance the salience of reward-related cues and play a role in the reinforcement enhancing effects of nicotine. Further supporting this hypothesis, systemic antagonism of nAChRs decreases nicotine-induced enhancement of reinforcers, although the brain regions necessary for this effect have not yet been established^[@CR15],[@CR16]^.

Repeated exposure to nicotine upregulates nAChRs in the striatum^[@CR17],[@CR18]^. Repeated nicotine also alters nAChR modulation of dopamine in the striatum. Two studies found that chronic oral nicotine self-administration in mice decreases electrically-stimulated dopamine release in the NAc core^[@CR19],[@CR20]^. The same studies also found that oral nicotine self-administration decreased the influence of β2-containing nAChRs^[@CR19]^ and α6-containing nAChRs^[@CR20]^ over dopamine release in the NAc core. Repeated nicotine also decreases α6β2\* receptor control over dopamine release in the NAc shell and ventral putamen of nonhuman primates^[@CR21],[@CR22]^.

Dopamine release in the NAc core is necessary for the incentive motivation of cues^[@CR23]^ and cue-induced drug seeking^[@CR24],[@CR25]^. Given the importance of nAChRs in modulating NAc dopamine release and their role in the dual-reinforcement effects of nicotine, chronic nicotine may modulate dopamine signals in a manner that drives further cue-induced drug seeking and use. Moreover, prior work has established that the pattern of intake or administration of psychostimulants, such as cocaine, is a primary determinant for changes in dopamine release magnitude^[@CR26]^. For example, schedules of reinforcement that lead to more continuous cocaine intake drive decreases in dopamine release^[@CR26]--[@CR29]^ similar to what has been shown with mini-pumps or oral administration of nicotine. Intermittent patterns of cocaine intake, however, lead to increased dopamine release^[@CR26],[@CR30],[@CR31]^. One purpose of the current study is to investigate whether an intermittent administration regimen leads to dichotomous changes in dopamine release compared to previous work using minipumps or oral nicotine administration.

Our lab has recently shown individual variation in the degree to which nAChRs modulate dopamine release in the NAc core and that this variation correlates with a behavioral measure of vulnerability to high levels of early drug intake^[@CR32]^. Additionally, it has been hypothesized that locomotor sensitization to nicotine is a marker of vulnerability to nicotine addiction^[@CR33]^. Given our previous work, we were also interested in whether individual differences in nicotine-induced locomotor sensitization would correlate with nicotine-induced changes in nAChR modulation of dopamine release.

To examine the effects of chronic nicotine on nAChR modulation of dopamine release in the NAc core, we used *ex vivo* fast-scan cyclic voltammetry (FSCV) to measure dopamine release in rats following seven days of once daily nicotine injections. Various stimulation parameters were used to model a range of dopamine neuron firing patterns. Then, non-selective and selective nAChR antagonists were used to examine whether repeated nicotine altered nAChR modulation of NAc dopamine release. We then assessed whether the magnitude of locomotor sensitization following repeated nicotine correlated with baseline dopamine or nicotine-induced modulation of dopamine release across tonic and phasic stimulations.

Results {#Sec2}
=======

Repeated nicotine exposure decreases dopamine release in the NAc core {#Sec3}
---------------------------------------------------------------------

We first examined whether repeated exposure to nicotine altered dopamine release in the NAc core. Rats were exposed to nicotine (0.2 or 0.4 mg/kg, s.c.) for seven consecutive days, then *ex vivo* FSCV was used to assess dopamine release in the NAc core the day after the final injection of nicotine (Fig. [1A](#Fig1){ref-type="fig"}). Repeated injections of nicotine significantly decreased the magnitude of dopamine evoked by a single pulse (main effect of group: *F*~2,45~ = 5.058, p = 0.01), with no significant difference between the doses of nicotine (Fig. [1B](#Fig1){ref-type="fig"}). Dopamine release was elicited by five pulse stimulations across the range of physiological dopamine neuron firing in order to examine dopamine signaling at frequencies that model tonic- and phasic-like firing patterns. As expected, frequency of the five pulse stimulation modulates dopamine release (main effect of frequency: *F*~4,184~ = 92.86, p \< 0.001), with higher frequencies increasing dopamine release. In concurrence with the single pulse dopamine release, repeated nicotine decreased dopamine release across the range of frequencies (main effect of group: *F*~2,46~ = 4.964, p = 0.011) and the decrease in dopamine release was not different between the doses of nicotine (Fig. [1C](#Fig1){ref-type="fig"}). The maximal rate of dopamine uptake (*V*max) was not impacted by repeated exposure to nicotine (*F*~2,41~ = 0.528, p = 0.594) (Fig. [1D](#Fig1){ref-type="fig"}). Given that the dose of nicotine did not differentially impact the magnitude of decrease in dopamine release, we focused only on the 0.4 mg/kg dose of nicotine in subsequent experiments.Figure 1Chronic nicotine administration lowers dopamine signaling. (**A**) Experimental timeline of locomotor assessments, nicotine injections, and voltammetry. Rats were given subcutaneous injections of saline or 0.2 mg/kg or 0.4 mg/kg nicotine for seven days, with locomotor assessment on Days 1 and 7. On the eighth day, brains were extracted and *ex vivo* voltammetry was used to examine dopamine release in the nucleus accumbens core. (**B**) Chronic exposure to nicotine lowers electrically-stimulated single pulse dopamine release compared to saline. (**C**) Nicotine decreases both dopamine release, but does not differ between doses. (**D**) Maximal rate of dopamine uptake (*V*~max~) is unaffected by nicotine exposure. Bars and symbols represent means ± SEMs, \*p \< 0.05.

α6-containing nAChR regulation of dopamine release is altered following repeated nicotine {#Sec4}
-----------------------------------------------------------------------------------------

To examine whether repeated exposure to nicotine had functional consequences on nAChR modulation of dopamine release in the NAc core, we assessed dopamine release across a range of frequencies following bath application of drugs that target nAChRs. Reductions in dopamine release to single pulse stimulations, in particular, could be attributed to reductions in acetylcholine (ACh) facilitation of dopamine release magnitude. Striatal cholinergic interneurons (CIN) increase dopamine release in the NAc core by activating nAChRs on dopamine terminals^[@CR5],[@CR6],[@CR34]^ and antagonism or desensitization of nAChRs decreases single pulse dopamine release^[@CR14]^. Nicotine decreased electrically stimulated dopamine release in both saline- and nicotine-treated animals (one-sample t-test against baseline (100%) saline: *t*~19~ = 14.02, p \< 0.001; nicotine: *t*~13~ = 7.984, p \< 0.001), indicating that a history of nicotine exposure did not cause baseline desensitization of nAChRs (Fig. [2A](#Fig2){ref-type="fig"}). Surprisingly, a history of nicotine exposure did not alter the magnitude of decrease in dopamine release to single pulse stimulations following a desensitizing dose of nicotine (*t*~32~ = 0.098, p = 0.922) (Fig. [2A](#Fig2){ref-type="fig"}) or MEC (a non-selective nAChR antagonist) (*t*~12~ = 0.87, p = 0.401) (Fig. [2B](#Fig2){ref-type="fig"}).Figure 2Chronic nicotine alters α6β2 nAChR modulation of dopamine following single pulse stimulation. (**A**) Chronic nicotine exposure did not alter the effect of a desensitizing concentration of nicotine (500 nM) or (**B**) MEC \[a non-selective nAChR antagonist (2 μM)\] on single pulse dopamine release in the NAc core. (**C**) DHβE \[a selective β2 nAChR antagonist (500 nM)\] decreased dopamine release significantly more in saline than nicotine treated rats. (**D**) Chronic nicotine exposure also blunted the decrease in single pulse dopamine release following application of α-Ctx MII \[a selective α6 nAChR antagonist (100 nM)\] followed by DHβE. This order was used to differentiate the effect of α6 and non-α6 nAChRs. Bars and symbols represent means ± SEMs, \*p \< 0.05.

We next used selective nAChR antagonists to examine whether β2\* nAChR-modulation of dopamine was altered by repeated exposure to nicotine since β2-containing nAChRs are necessary for the reinforcing effects of nicotine and for nicotine-induced increases in NAc dopamine^[@CR35],[@CR36]^. To determine this, we examined dopamine release following a bath application of DHβE \[a β2-selective antagonist (500 nM)\]. A history of nicotine exposure significantly blunted the decreasing effects of DHβE on single pulse dopamine release (*t*~26~ = 3.269, p = 0.003)(Fig. [2C](#Fig2){ref-type="fig"}). To examine the contribution of α6\* and non-α6\* β2-containing nAChRs to the changes in β2-containing nAChR modulation of dopamine, we applied α-Ctx MII \[a selective α6 antagonist (100 nM)\] followed by DHβE. Consistent with the DHβE results above, saline treated animals had a significantly greater decrease of single pulse dopamine release following treatment with α-Ctx MII alone (solid bars) and α-Ctx MII + DHβE (main effect of group: *F*~1,10~ = 8.358, p = 0.016). DHβE did not significantly modulate the effect of α-Ctx MII on dopamine release in either group (main effect of drug: *F*~1,10~ = 0.012, p = 0.914; interaction group\*drug: *F*~1,10~ = 1.293, p = 0.282).

Since nAChRs modulate dopamine release in a frequency dependent manner and the effects of cholinergic and nicotine-induced modulation of dopamine on behavior are hypothesized to be mediated by frequency-dependent gating of dopamine^[@CR14]^, we wanted to examine the effects of nicotine and non-selective and selective nAChR antagonists across a range of physiologically relevant frequencies in the NAc core (Fig. [3A](#Fig3){ref-type="fig"}). To determine this, we used five pulse stimulations across a range of frequencies to model tonic- and phasic-like firing patterns before and after nicotine or nAChR antagonism. As expected, nicotine modulated dopamine release in a frequency-dependent manner, decreasing dopamine release to single pulse and low frequency stimulation, but not to the highest frequency stimulation (interaction drug\*frequency: *F*~4,124~ = 15.383, p \< 0.001). However, repeated nicotine exposure did not change nicotine-induced modulation of dopamine release (main effect of group: *F*~1,31~ = 0.026, p = 0.874)(Fig. [3B](#Fig3){ref-type="fig"}). Similar to the effects of nicotine, MEC decreased single pulse and low frequency dopamine release, but did not affect high frequency dopamine release, and this modulation was not changed by a history of nicotine exposure (main effect of group: *F*~1,13~ = 0.001, p = 0.982; interaction drug\*frequency: *F*~4,\ 52~ = 5.419, p = 0.001)(Fig. [3C](#Fig3){ref-type="fig"}).Figure 3α6 nAChR modulation of dopamine release is altered following chronic nicotine. (**A**) Schematic of local circuitry and nAChRs located in the NAc core. (**B**) Nicotine (500 nM) decreased dopamine release to single pulse and low frequency stimulation, but not the highest stimulation frequency. Chronic nicotine exposure did not change nicotine-induced modulation of dopamine release. (**C**) MEC (2 μM) decreased dopamine release to single pulse and low frequency stimulation in both saline and nicotine treated animals. (**D**) DHβE (500 nM) and (**E**) α-Ctx MII (100 nM) also modulate dopamine release in a frequency-dependent manner, but dopamine release is higher in rats with chronic nicotine exposure and shows facilitation at higher frequencies. (**F**) The application of DHβE following α-Ctx MII does not significantly change dopamine release. Bars and symbols represent means ± SEMs, \*p \< 0.05. Note: Not all significant interactions are visually represented.

To determine the role of β2-containing nAChRs and isolate the role of α6 and non-α6 containing β2\* nAChRs on dopamine release to tonic and phasic firing patterns, we applied DHβE alone and following application of α-Ctx MII. As with nicotine, DHβE decreased dopamine to single pulse and low frequency stimulations, but not to the highest frequency stimulations (interaction drug\*frequency: *F*~4,104~ = 22.468, p \< 0.001). Interestingly, DHβE decreased dopamine release across the range of stimulation frequencies significantly more in saline treated rats than rats with repeated nicotine exposure (interaction drug\*group: *F*~1,26~ = 7.608, p = 0.011) (Fig. [3D](#Fig3){ref-type="fig"}). In agreement with this effect being driven by α6-containing nAChRs, dopamine release was significantly higher in rats with repeated nicotine exposure following α-Ctx MII application (interaction drug\*group: *F*~1,10~ = 4.905, p = 0.05) (Fig. [3E](#Fig3){ref-type="fig"}). Additionally, DHβE did not significantly affect dopamine release in saline or nicotine treated rats when applied after α-Ctx MII (main effect of drug: *F*~1,8~ = 0.739, p = 0.415), although rats with repeated nicotine exposure did have higher dopamine release than saline treated rats at the two highest frequency stimulations following α-Ctx MII and subsequent DHβE (interaction group\*frequency: *F*~4,32~ = 4.148, p = 0.008) (Fig. [3F](#Fig3){ref-type="fig"}).

The relationship between tonic and phasic dopamine release is important for reward-related learning and the increase in phasic/tonic ratio following nicotine application is thought to play a role in the reinforcement-enhancing effects of nicotine^[@CR14]^. We next examined whether a history of nicotine exposure impacted the change in phasic/tonic ratios following application of nicotine or nAChR antagonists. As expected, bath application of nicotine or nAChR antagonists increased the phasic/tonic ratio compared to baseline measures (main effect of drug nicotine: *F*~1,31~ = 16.52, p = 0.003; MEC: *F*~1,12~ = 10.76, p = 0.007; DHβE: *F*~1,\ 24~ = 24.91, p \< 0.001; Ctx + DHβE: *F*~2,16~ = 18.52, p \< 0.001). However, a history of nicotine exposure did not impact phasic/tonic ratios or how nicotine and nAChR antagonists alter phasic/tonic rations (all p \> 0.05) (Fig. [4A--D](#Fig4){ref-type="fig"}).Figure 4Chronic nicotine does not alter enhancement of dopamine phasic:tonic ratios caused by nAChR modulation on a slice. Nicotine (**A**), MEC (**B**), DHβE (**C**), and α-ctx (**D**) all enhance dopamine phasic:tonic ratios (5 P @ 20 Hz/1 P) equally in both saline and nicotine treated animals.

The magnitude of nicotine sensitization predicts nicotine-induced modulation of striatal dopamine release at phasic firing frequencies {#Sec5}
--------------------------------------------------------------------------------------------------------------------------------------

Repeated exposure to nicotine increases nicotine-induced locomotion and nicotine sensitization is hypothesized to be a marker of vulnerability to nicotine addiction^[@CR33]^. Previous work from our lab has shown that nAChR modulation of dopamine release in the NAc core correlates with another model of vulnerability (high and low responders)^[@CR32]^. Because of these findings, we were interested in whether nAChR modulation of dopamine release may predict locomotor sensitization following repeated nicotine exposure. Acute nicotine and repeated saline did not affect locomotion. As expected, repeated nicotine injections increased locomotion following a nicotine injection, but did not alter baseline locomotion (interaction drug\*time\*day: *F*~20,1020~ = 4.994, p \< 0.001) (Fig. [5A](#Fig5){ref-type="fig"}). Repeated injections of nicotine significantly increased nicotine-induced locomotion (one-sample t-test: *t*~31~ = 7.31, p \< 0.001), while repeated saline did not alter locomotion following a saline injection (one sample t-test: *t*~21~ = 0.881, p = 0.388) (Fig. [5A](#Fig5){ref-type="fig"}).Figure 5The magnitude of nicotine-induced sensitization predicts the effects of nicotine on dopamine release to phasic firing in the NAc. (**A**) Nicotine increases post-injection locomotion significantly more following repeated nicotine exposure. Repeated saline and acute nicotine do not alter locomotion. Inset: Repeated injections of nicotine significantly changed nicotine-induced locomotion, while repeated injections of saline did not change locomotion following a saline injection. (**B**,**C**) The magnitude of nicotine-induced locomotor sensitization is not predicted by baseline dopamine release following 5 Hz (**B**) or 20 Hz (**C**) stimulations. (**D**) Magnitude of nicotine-induced locomotor sensitization is not predicted by changes in tonic (5 Hz) stimulations following bath application of nicotine (500 nM), (**E**) but is predicted by nicotine-induced changes to dopamine release following phasic (20 Hz) stimulation. (**F**) Similarly, magnitude of nicotine locomotor sensitization was not correlated with MEC-induced (2 μM) changes in dopamine release to tonic stimulation, (**G**) but did positively correlate with changes to phasic dopamine release following MEC application. Bars and symbols represent means  ± SEMs, \*p \< 0.05.

We next wanted to investigate whether nicotine on a slice would affect dopamine in a manner similar to the differential effects on locomotor activity. There was individual variation in how much repeated nicotine sensitized nicotine-induced locomotion. We examined whether locomotor sensitization to nicotine predicted the effects of baseline dopamine release or nicotine on dopamine release in the NAc core. Locomotor sensitization to nicotine did not predict baseline dopamine release to stimulations modeling tonic (5 Hz) or phasic (20 Hz) firing (5 Hz: r = −0.061, p = 0.798; 20 Hz: r = 0.044, p = 0.852) (Fig. [5B,C](#Fig5){ref-type="fig"}). Additionally, locomotor sensitization to nicotine did not correlate with the effects of nicotine on tonic frequency stimulation of dopamine (5 Hz: r = 0.514, p = 0.088) (Fig. [5D](#Fig5){ref-type="fig"}), but did correlate with nicotine-induced modulation of dopamine following phasic firing rates (20 Hz: r = 0.632, p = 0.028) (Fig. [5E](#Fig5){ref-type="fig"}). In agreement with the effects of nicotine, locomotor sensitization did not correlate with MEC-induced modulation of dopamine release to tonic firing rates (5 Hz: r = 0.488, p = 0.326) (Fig. [5F](#Fig5){ref-type="fig"}), but did correlate with dopamine release to phasic firing stimulation (20 Hz: r = 0.87, p = 0.024) (Fig. [5G](#Fig5){ref-type="fig"}).

Discussion {#Sec6}
==========

Our results indicate that repeated nicotine administration (0.2 and 0.4 mg/kg) decreases dopamine release during both single pulse stimulation and multiple pulse stimulations across a range of frequencies that model tonic and phasic firing of dopamine neurons. Moreover, repeated nicotine did not alter the frequency dependent nature of dopamine release magnitude. These results are consistent with previous published reports showing decreases in dopamine release in the NAc and caudate-putamen in mice following several weeks of oral nicotine treatment^[@CR19],[@CR20]^ and the NAc shell and ventral putamen of squirrel monkeys following several months of oral nicotine treatment^[@CR21],[@CR22]^. One purpose of our study was to extend this prior work by investigating whether these changes would occur using a model of repeated, intermittent nicotine injections, which more closely mimics the rapid rate of nicotine delivery and pharmacokinetics seen with smoking than oral administration^[@CR20],[@CR22],[@CR37],[@CR38]^. Other psychostimulants, such as cocaine, alter dopamine release magnitude in a manner that is dependent on the pattern of intake or administration. Intermittent patterns lead to an increase, and more continuous exposure leading to a decrease, in dopamine release. In this regard, nicotine may be unlike administration of other psychostimulants like cocaine since this administration pattern lead to decreases in dopamine release. Indeed, our model of seven days of intermittent nicotine injections in rats produced a magnitude of dopamine reduction similar to the effect sizes from more continuous administration paradigms in monkeys and mice. Additionally, our effects were not due to differences in dopamine uptake through the dopamine transporter since Vmax was not changed by nicotine exposure.

We next examined the degree to which these nicotine-induced reductions in dopamine release could be attributed to reductions in ACh facilitation of dopamine release magnitude. CINs supply abundant ACh to the NAc, which can facilitate dopamine release magnitude via nAChRs located directly on dopamine axons^[@CR14]^. Acute β2\* blockade or desensitization lowers the probability of dopamine release in response to single pulse and multiple pulse stimulations that model tonic firing of dopamine neurons^[@CR10],[@CR14],[@CR39]^. α6β2-containing nAChRs dominate ACh influence over dopamine release in the ventral striatum/NAc core, while α5-containing nAChRs play a larger role in the dorsal striatum^[@CR40]^. Previous work investigating dopamine changes following oral nicotine intake demonstrated selective blunting of α6-containing nAChR control over dopamine release. Thus, we hypothesized that if ACh release from CINs was blunted (or has less influence over dopamine release) in the NAc core following repeated nicotine injections, then both β2 and α6 selective antagonists would be less effective at reducing dopamine release in nicotine treated rats compared to saline treated rats. Consistent with this hypothesis and previous work, both the β2 selective antagonist, DHβE, and the α6 selective antagonist, α-Ctx MII, were less effective at reducing dopamine release in animals treated with nicotine. The nonselective antagonist, MEC, and a desensitizing dose of nicotine decreased dopamine equally in both saline and repeated nicotine groups. The difference in outcome between these nonselective (or desensitizing) compounds and the α6β2 selective compounds is unclear. One major difference between these classes of drugs is that the nonselective compounds also bind α7 nAChRs, which are located on glutamate afferents in our slice preparation and could effectively reduce excitatory drive onto dopamine axons when blocked or desensitized with mecamylamine or nicotine, respectively. A reduction in excitatory drive on dopamine axons has the potential to decrease dopamine release to floor effects and mask the α6β2\* mediated effects observed using our selective antagonists. Moreover, previous work has demonstrated that repeated nicotine administration decreases α6-containing nAChRs in the striatum^[@CR41],[@CR42]^, and affects β2-containing nAChR expression throughout the brain more so than α7 nAChRs. Perhaps effects observed here are due to a selective shift in expression of α6-containing nAChRs on dopamine axons in the striatum following intermittent exposure, leading to the blunted functional effect observed after α6 blockade. Regardless, the involvement of α6β2\* nAChRs is consistent with previous voltammetric studies that showed α6β2-containing receptors are primarily responsible for nAChR-evoked dopamine release in the ventral striatum^[@CR40]^. This is further supported by the fact that DHβE had no effect on dopamine release magnitude when administered after α-Ctx MII, suggesting minimal contribution from non-α6 containing nAChRs^[@CR32],[@CR40]^ to our nicotine treatment differences in dopamine release.

We next examined whether repeated nicotine injections sensitized locomotor response to nicotine challenge, as previously reported^[@CR33]^, and whether the degree to which sensitized locomotor activity relates to the magnitude of nicotine's effect on NAc phasic signals in a slice. We show that a seven-day regimen of once daily nicotine injections (0.4 mg/kg, s.c.) sensitizes locomotor activity, with nicotine treated rats more than doubling their locomotor activity after the sixth nicotine injection compared to the first. Although elevations in locomotor activity are the most robust ≤15 minutes post injection, elevations are sustained through the entire session. We also found that the magnitude of nicotine-induced locomotor sensitization is not predicted by changes in tonic (5 Hz) stimulations following bath application of either nicotine or MEC, but did positively correlate with changes to phasic (20 Hz) dopamine release with both nicotine and MEC. This data is particularly interesting given our previous data that phasic, but not tonic, dopamine release magnitude following bath application of nicotine and MEC correlates with locomotor response to novelty^[@CR32]^, a strong predictor of acquisition rates for several drugs of abuse^[@CR43]--[@CR45]^. Thus, nicotine modulation of NAc core phasic dopamine release correlates with two markers of vulnerability to substance use disorders: one in drug naïve animals and one following repeated drug exposure. This generality suggests that striatal nAChR modulation of NAc core dopamine (or the interaction of striatal acetylcholine and dopamine) may be a potential biomarker of vulnerability to SUD, or directly mediate SUD vulnerability. Indeed, recent work has shown mechanistic links between ACh signaling through nAChRs on dopamine axons and modulation of cue-induced motivation for natural rewards^[@CR46]^. Future studies will need to explore whether such findings extend to drug seeking.

In conclusion, we found that repeated, intermittent nicotine injections blunt dopamine release equally across a range of stimulation frequencies that model both tonic and phasic firing of dopamine neurons and that repeated nicotine decreased the ability of α6β2-containing nAChRs to modulate dopamine release. This deficit in dopamine function may underlie, in part, increased vulnerability to nicotine use following repeated exposure to nicotine. In particular, CIN modulation of dopamine release (mediated through nAChRs) is thought to be essential for reward-related learning^[@CR47]^ and dysregulation of this system may alter responses to rewards (i.e., nicotine) and reward-related cues in a manner that drive nicotine use disorder. We also extended our earlier work on the relationships between locomotor response to either novelty or acute nicotine and dopamine release magnitude following nicotine administration in the NAc. Indeed, we found that nicotine locomotor sensitization, a potential marker of vulnerability to nicotine dependence, correlates with nicotine and MEC modulation of phasic dopamine release. Together, these data suggest that repeated nicotine exposure alters nAChR control over dopamine release in the NAc core in a manner that is consistent with changes that may serve as a biomarker for vulnerability to nicotine use, or a mechanism for such vulnerability.

Materials and Methods {#Sec7}
=====================

Animals {#Sec8}
-------

Adult male Sprague-Dawley rats (325--350 grams, Harlan Sprague Dawley, Inc., Madison, WI) were maintained on a 12:12 h reverse light/dark cycle (4:00 a.m. lights off; 4:00 p.m. lights on) with food and water available *ad libitum*. All animals were maintained according to the National Institutes of Health guidelines in Association for Assessment and Accreditation of Laboratory Animal Care accredited facilities. The experimental protocol was approved by the Institutional Animal Care and Use Committee at Wake Forest School of Medicine.

Locomotor assessment and nicotine exposure {#Sec9}
------------------------------------------

Rats were given at least a week to acclimate to the housing environment and light cycle prior to the start of experiments. All locomotor testing occurred during the dark/active cycle (9:00AM) to prevent sleep from contributing to variability in locomotor activity. Rats were first transferred to the dark locomotor testing room for one hour to habituate in their home cages. They were then placed in an acrylic locomotor activity chamber (45.7 cm × 45.7 cm × 30.4 cm) where their locomotor activity was monitored for 90 minutes. Rats were then subcutaneously injected on the flank with 0.9% saline solution, 0.2 mg/kg nicotine, or 0.4 mg/kg nicotine and replaced in the activity chamber for another 90 minutes. Nicotine (0.2--0.4 mg/kg, s.c.) or saline was administered for an additional six consecutive days during their active/dark cycle. On the seventh (last) day, locomotion was reassessed as on day one. Activity was recorded using Noldus^®^ video camera system and analyzed using EthoVision XT (version 11.5).

*Ex vivo* fast scan cyclic voltammetry {#Sec10}
--------------------------------------

The day after the final injection, rats were anesthetized with isoflurane and euthanized by decapitation. Brains were rapidly removed and transferred into ice-cold, pre-oxygenated (95% O~2~/5% CO~2~) artificial cerebral spinal fluid (aCSF) containing (in mM): NaCl (126), KCl (2.5), monobasic NaH~2~PO~4~ (1.2), CaCl~2~ (2.4), MgCl~2~ (1.2), NaHCO~3~ (25), dextrose (D-glucose) (11), and L-ascorbic acid (0.4). Tissue was sectioned into 400 μm-thick coronal striatal slices with a compresstome^®^ VF-300 vibrating microtome (Precisionary Instruments, San Jose, California). Brain slices were placed in submersion recording chambers and then perfused at 1 mL/min at 32 °C with oxygenated aCSF.

FSCV was used to assess dopamine release in the NAc core in rat brain slices (Fig. [1A](#Fig1){ref-type="fig"}). A bipolar stimulating electrode was placed 100--150 μM from a carbon-fiber recording electrode (100--200 μm length, 7 µm diameter) in the NAc core (Fig. [1A](#Fig1){ref-type="fig"}). Dopamine release was initially evoked by a single electrical pulse (750 μA, 2 msec, monophasic) applied to the tissue every 3 minutes.

Extracellular dopamine was recorded by applying a triangular waveform from −0.4 to 1.2 V and back to −0.4 (Ag vs AgCl) at a scan rate of 400 V/s using by a carbon fiber electrode. Voltammograms were recorded at the carbon fiber electrode every 100 msec. Once dopamine response was stable (three consecutive collections with \<10% variability), five-pulse stimulations were applied at varying burst frequencies (5, 10, 20, or 100 Hz) to model the physiological range of dopamine neuron firing. After assessing the dopamine response to single and multi-pulse stimulations, various compounds targeting nAChRs (nicotine, 500 nM; mecamylamine \[MEC\], 2 μM; dihydro-beta-erythroidine \[DHβE\], 500 nM; α-conotoxin MII \[α-Ctx MII\], 100 nM) were bath applied and dopamine response equilibrated (three collections within 10% variability) to single pulse stimulation. Separate slices from the same animal were used to test each drug independently, and the same frequency-response curves assessed under drug-free conditions were reassessed following drug application in each slice. In order to test the distinct contributions of α6\* and non-α6\* nAChRs, we added α-Ctx MII and DhβE in a cumulative fashion, equilibrating and testing single and multi-pulse frequencies (described above) following α-Ctx MII and then DhβE. Changes in dopamine signaling between α-Ctx MII \[a selective α6 nAChR antagonist^[@CR48]^\] alone and in combination with DHβE (a β2 nAChR antagonist) differentiated the contribution of α6\* and non-α6\* β2-containing nAChRs. We focused on nAChRs containing α6 subunits due to its role in modulating dopamine release in the NAc^[@CR32],[@CR49]^.

Demon Voltammetry and Analysis software was used to acquire and model FSCV data^[@CR50]^. Recording electrodes were calibrated by recording electrical current responses (in nA) to a known concentration of dopamine (3 μM) using a flow-injection system. This was used to convert electrical current to dopamine concentration. Michaelis-Menten kinetics were used to determine maximal rate of dopamine uptake (*V*max)^[@CR51]^.

Statistical analysis {#Sec11}
--------------------

Single pulse dopamine release and *V*max were compared by one-way ANOVA and Tukey's multiple comparison in case of significance. Dopamine release across multiple frequency stimulations was normalized to each subject's pre-drug single pulse dopamine release. Multi-pulse dopamine release and locomotor activity were compared by two- or three-factor mixed design ANOVA. In the case of significant interactions, Bonferroni post-hoc comparisons were used. Percent changes in dopamine release following drug application were compared using two-tailed unpaired *t*-tests or two-factor mixed design ANOVA. Locomotor sensitization was assessed using one-sample *t*-tests against no change. Pearson product-moment correlation was used to assess the relationship between nicotine locomotor sensitization and nicotine- and MEC-induced modulation of dopamine release. All statistics were performed using GraphPad Prism 7 (Graphpad Software, La Jolla, CA) or SPSS v. 24 (International Business Machine Corporation, Armonk, NY) with α ≤ 0.05. Values \>2 standard deviations above or below the mean were considered outliers and excluded. Data are presented as mean ± SEM.
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